Orlance, Inc. awarded RNA Vaccine Development Grant
SEATTLE, July 10, 2024 /PRNewswire/ -- Seattle-based biotech Orlance, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop and optimize RNA vaccine formulations using its needle-free MACH-1™ platform. This...
SEATTLE, July 10, 2024 /PRNewswire/ -- Seattle-based biotech Orlance, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop and optimize RNA vaccine formulations using its needle-free MACH-1™ platform. This...
